A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Trial details
- Registry ID
- NCT06302348
- Phase
- Phase 3
The FDA approved Sepiapterin (PTC923) on 28 Jul 2025.
Drug identity checked against registry records
Also recorded as PTC923; Sephience
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Sepiapterin in Participants With Phenylketonuria (PKU)NCT06302348 | PTC Therapeutics | Phase 3 | Recruiting | 2031-02-28Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2025-07-28Day | Sepiapterin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA219666", "applicant_as_listed_by_fda": "PTC THERAP", "brand_names": ["SEPHIENCE"], "active_ingredients": ["SEPIAPTERIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20250728", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |